GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exelixis Inc (NAS:EXEL) » Definitions » Shiller PE Ratio
中文

Exelixis (Exelixis) Shiller PE Ratio : 64.08 (As of Apr. 24, 2024)


View and export this data going back to 2000. Start your Free Trial

Exelixis Shiller PE Ratio Definition

As of today (2024-04-24), Exelixis's current share price is $23.71. Exelixis's E10 for the quarter that ended in Dec. 2023 was $0.37. Exelixis's Shiller PE Ratio for today is 64.08.

The historical rank and industry rank for Exelixis's Shiller PE Ratio or its related term are showing as below:

EXEL' s Shiller PE Ratio Range Over the Past 10 Years
Min: 54.65   Med: 109.94   Max: 690.67
Current: 64.08

During the past years, Exelixis's highest Shiller PE Ratio was 690.67. The lowest was 54.65. And the median was 109.94.

EXEL's Shiller PE Ratio is ranked worse than
74.31% of 144 companies
in the Biotechnology industry
Industry Median: 32.84 vs EXEL: 64.08

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Exelixis's adjusted earnings per share data for the three months ended in Dec. 2023 was $0.270. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $0.37 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Exelixis Shiller PE Ratio Historical Data

The historical data trend for Exelixis's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exelixis Shiller PE Ratio Chart

Exelixis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 122.92 64.32

Exelixis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 122.92 110.39 77.32 73.58 64.32

Competitive Comparison of Exelixis's Shiller PE Ratio

For the Biotechnology subindustry, Exelixis's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exelixis's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exelixis's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Exelixis's Shiller PE Ratio falls into.



Exelixis Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Exelixis's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=23.71/0.37
=64.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exelixis's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Exelixis's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.27/129.4194*129.4194
=0.270

Current CPI (Dec. 2023) = 129.4194.

Exelixis Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -0.390 99.695 -0.506
201406 -0.380 100.560 -0.489
201409 -0.320 100.428 -0.412
201412 -0.300 99.070 -0.392
201503 -0.180 99.621 -0.234
201506 -0.220 100.684 -0.283
201509 -0.210 100.392 -0.271
201512 -0.190 99.792 -0.246
201603 -0.260 100.470 -0.335
201606 -0.150 101.688 -0.191
201609 -0.040 101.861 -0.051
201612 0.120 101.863 0.152
201703 0.050 102.862 0.063
201706 0.060 103.349 0.075
201709 0.260 104.136 0.323
201712 0.120 104.011 0.149
201803 0.370 105.290 0.455
201806 0.280 106.317 0.341
201809 0.410 106.507 0.498
201812 1.150 105.998 1.404
201903 0.240 107.251 0.290
201906 0.250 108.070 0.299
201909 0.310 108.329 0.370
201912 0.220 108.420 0.263
202003 0.150 108.902 0.178
202006 0.210 108.767 0.250
202009 -0.100 109.815 -0.118
202012 0.090 109.897 0.106
202103 0.005 111.754 0.006
202106 0.300 114.631 0.339
202109 0.120 115.734 0.134
202112 0.290 117.630 0.319
202203 0.210 121.301 0.224
202206 0.220 125.017 0.228
202209 0.230 125.227 0.238
202212 -0.090 125.222 -0.093
202303 0.120 127.348 0.122
202306 0.250 128.729 0.251
202309 0.003 129.860 0.003
202312 0.270 129.419 0.270

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Exelixis  (NAS:EXEL) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Exelixis Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Exelixis's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Exelixis (Exelixis) Business Description

Traded in Other Exchanges
Address
1851 Harbor Bay Parkway, Alameda, CA, USA, 94502
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
Executives
Patrick J. Haley officer: Sr. Vice President, Commercial 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Jeffrey Hessekiel officer: EVP and General Counsel 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
David Edward Johnson director 590 MADISON AVENUE, NEW YORK NY 10022
Dana Aftab officer: CSO/EVP Disc & Trans Research EXELIXIS, INC., 1851 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Amy C. Peterson officer: EVP Prod Dev & Med Aff & CMO C/O MOURANT OZANNES CORPORATE SERVICES, 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN E9 KY1-1108
Christopher J. Senner officer: EVP and CFO 210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Tomas J. Heyman director C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Bob Oliver director C/O IMMUNOMEDICS, INC., 300 THE AMERICAN ROAD, MORRIS PLAINS NJ 07950
Caligan Partners Lp director, other: See Remarks 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Jack L Wyszomierski director SCHERING PLOUGH CORP, ONE GIRALDA FARMS, MADISON NJ 07940-1000
Alan M Garber director 3355 MILTON COURT, MOUNTAIN VIEW CA 94040
Carl B Feldbaum director C/O EXELIXIS INC, 170 HARBOR WAY, PO BOX 511, SOUTH SAN FRISCISCO CA 94083-0511
Peter Lamb officer: EVP, Discovery Research & CSO PO BOX 511, 170 HARBOR WAY, SOUTH SAN FRANCISCO CA 94083-0511
George Poste director 515 GALVESTON DR, REDWOOD CITY CA 94063
Lance Willsey director C/O EXELIXIS INC, 170 HARBOR WAY, SAN FRANCISCO CA 94083